# | Title | Journal | Year | Citations |
---|
|
1 | Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual | Ca-A Cancer Journal for Clinicians | 2017 | 1,748 |
2 | Whole-genome landscapes of major melanoma subtypes | Nature | 2017 | 1,120 |
3 | PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma | New England Journal of Medicine | 2018 | 1,072 |
4 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) | Lancet, The | 2017 | 1,066 |
5 | [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial | Lancet, The | 2021 | 629 |
6 | Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy | Cancer Cell | 2019 | 620 |
7 | Polychemotherapy in advanced non small cell lung cancer: a meta-analysis | Lancet, The | 1993 | 494 |
8 | A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer | British Journal of Cancer | 2012 | 399 |
9 | Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial | Lancet Oncology, The | 2015 | 339 |
10 | Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial | Lancet Oncology, The | 2020 | 334 |
11 | Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy | JAMA Oncology | 2019 | 307 |
12 | High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy | Clinical Cancer Research | 2010 | 285 |
13 | Cancer Patient Disclosure and Patient-Doctor Communication of Complementary and Alternative Medicine Use: A Systematic Review | Oncologist | 2012 | 273 |
14 | Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study | Lancet Oncology, The | 2010 | 268 |
15 | 68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment | BJU International | 2016 | 242 |
16 | Fertility- and Menopause-Related Information Needs of Younger Women With a Diagnosis of Early Breast Cancer | Journal of Clinical Oncology | 2005 | 235 |
17 | Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies | JAMA Oncology | 2018 | 235 |
18 | Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial | Lancet Oncology, The | 2020 | 230 |
19 | miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer | Clinical Cancer Research | 2009 | 229 |
20 | Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance | Theranostics | 2017 | 215 |
21 | A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma | Neuro-Oncology | 2016 | 212 |
22 | Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma | Clinical Cancer Research | 2017 | 206 |
23 | Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib | Journal of Clinical Oncology | 2018 | 204 |
24 | Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications | Frontiers in Oncology | 2015 | 198 |
25 | A group cognitive behaviour therapy programme with metastatic breast cancer patients | Psycho-Oncology | 1999 | 194 |
26 | Survivorship care plans in cancer: a systematic review of care plan outcomes | British Journal of Cancer | 2014 | 188 |
27 | Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial | Supportive Care in Cancer | 2012 | 182 |
28 | Clinical Development of TargomiRs, a miRNA Mimic-Based Treatment for Patients with Recurrent Thoracic Cancer | Epigenomics | 2016 | 182 |
29 | Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial | Annals of Oncology | 2010 | 179 |
30 | The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies | Clinical Oncology | 2004 | 175 |
31 | Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma | Annals of Oncology | 2019 | 174 |
32 | Fatal pulmonary toxicity resulting from treatment with gemcitabine | Cancer | 1997 | 173 |
33 | Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinoma | International Journal of Radiation Oncology Biology Physics | 1995 | 169 |
34 | Bisphosphonates and other bone agents for breast cancer | The Cochrane Library | 2018 | 169 |
35 | Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium | Lancet Oncology, The | 2019 | 165 |
36 | A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer | British Journal of Cancer | 1990 | 163 |
37 | Effects of group CBT on the survival time of patients with metastatic breast cancer | Psycho-Oncology | 1999 | 155 |
38 | Anatomic Boundaries of the Clinical Target Volume (Prostate Bed) After Radical Prostatectomy | International Journal of Radiation Oncology Biology Physics | 2007 | 150 |
39 | Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy | Journal of Clinical Oncology | 2009 | 146 |
40 | Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer | Annals of Oncology | 2018 | 146 |
41 | Patterns of alternative medicine use by cancer patients | Medical Journal of Australia | 1996 | 144 |
42 | Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma | Annals of Oncology | 2014 | 139 |
43 | Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression | Clinical Genitourinary Cancer | 2019 | 137 |
44 | FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma | Annals of Oncology | 2018 | 132 |
45 | Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer | British Journal of Cancer | 2014 | 129 |
46 | Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients | Journal of Vascular and Interventional Radiology | 2012 | 122 |
47 | Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing | | 2020 | 122 |
48 | Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial | Lancet, The | 2001 | 120 |
49 | Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study | British Journal of Dermatology | 2020 | 119 |
50 | Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study | Cancer Chemotherapy and Pharmacology | 2017 | 114 |